诱导结束时微小残留病与T细胞淋巴母细胞淋巴瘤无事件生存:儿童肿瘤协作组AALL1231试验
AALL1231是一项儿童肿瘤协作组3期临床试验,针对初诊T细胞急性淋巴细胞白血病或T细胞淋巴母细胞淋巴瘤(T-LL)患者,随机分配至改良augmented Berlin-Frankfurt-Münster方案接受标准治疗(A组)或加用硼替佐米(B组)。209例T-LL患者中86例(41%)提交了诱导结束时(EOI)微小残留病(MRD)骨髓样本,MRD<0.1%者(n=75)4年无事件生存(EFS)优于MRD≥0.1%者(n=11)(89.0%±4.4% vs 63.6%±17.2%;P=.025),总生存两组无显著差异;以A组为参照的Cox回归显示MRD≥0.1%与更差结局风险相关(HR 3.73;95%CI 1.12-12.40;P=.032),且独立于治疗组分配。
要点
- T-LL患者EOI时MRD≥0.1%者4年EFS低于MRD<0.1%者(63.6%±17.2% vs 89.0%±4.4%;P=.025)
- EOI MRD≥0.1%与更差EFS相关(HR 3.73;95%CI 1.12-12.40;P=.032),独立于治疗组
- 两组总生存无显著差异
核心结论
- T-LL患者诱导结束时MRD≥0.1%与4年EFS inferior相关,且独立于治疗组分配;总生存两组无显著差异。
- 作者提出考虑将EOI MRD纳入未来试验,以帮助确立其在定义风险组中的价值。
研究设计与样本
- AALL1231为儿童肿瘤协作组3期临床试验,针对初诊T急性淋巴细胞白血病或T-LL患者,随机分配至改良augmented Berlin-Frankfurt-Münster方案标准治疗(A组)或加用硼替佐米(B组)。
- 209例T-LL患者中86例(41%)提交了可选骨髓样本用于EOI MRD评估,分析EOI MRD与EFS的相关性。
主要发现
- EOI MRD<0.1%者(n=75)4年EFS为89.0%±4.4%,MRD≥0.1%者(n=11)为63.6%±17.2%(P=.025)。
- 两组总生存无显著差异。
- 以A组为参照的Cox回归显示,EOI MRD≥0.1%与更差结局风险相关(HR 3.73;95%CI 1.12-12.40;P=.032),独立于治疗组分配。
临床怎么用
- 作者提出考虑将EOI MRD纳入未来试验,以帮助确立其在定义风险组中的价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.
引用
- Hayashi RJ, Hermiston ML, Wood BL, et al. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024. PMID: 38457359. doi:10.1182/blood.2023021184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。